Incyte Names New Member to Its Board of Directors
December 19 2019 - 7:30AM
Business Wire
Incyte (Nasdaq:INCY) announces the appointment of Edmund P.
Harrigan, M.D., as a new member of the Board of Directors,
effective December 16, 2019.
“We are delighted to welcome Edmund to Incyte. His extensive
leadership experience in a variety of important areas including
Clinical, Regulatory and Business Development will be instrumental
as we continue to develop and commercialize innovative medicines
for serious unmet medical conditions,” said Hervé Hoppenot, Chief
Executive Officer, Incyte. “We look forward to benefiting from his
valuable experience and further strengthening Incyte’s
leadership.”
“It is an exciting time to be joining Incyte as the company
strives to advance clinical candidates from its diverse portfolio,”
said Dr. Harrigan. “I look forward working closely with the team to
deliver on the company’s commitment to improving the lives of
patients worldwide and building sustainable value for
stakeholders.”
Dr. Harrigan served in various senior roles at Pfizer, Inc.,
including Senior Vice President of Worldwide Safety and Regulatory
from 2012 until his retirement in 2015. Dr. Harrigan’s previous
executive leadership roles at Pfizer included Senior Vice
President, Head of Worldwide Business Development; Senior Vice
President, Head of Worldwide Regulatory Affairs and Quality
Assurance; and Vice President, Head of Neuroscience and
Ophthalmology. In addition, he has served in senior leadership
positions at Karuna Pharmaceuticals, Inc., Sepracor Inc. and
Neurogen Corporation. Prior to joining the pharmaceutical industry
in 1990, Dr. Harrigan was a practicing neurologist for seven years.
Dr. Harrigan earned his B.A. in Chemistry from St. Anselm College
and M.D. from University of Massachusetts.
About Incyte
Incyte is a Wilmington,
Delaware-based, global biopharmaceutical company focused on finding
solutions for serious unmet medical needs through the discovery,
development and commercialization of proprietary therapeutics. For
additional information on Incyte, please visit Incyte.com and
follow @Incyte.
Forward-Looking Statements
Except for the historical information set forth herein, the
matters set forth in this press release, including without
limitation statements regarding the Company’s efforts to advance
its clinical pipeline, improve the lives of patients and build
value for stakeholders contain predictions, estimates and other
forward-looking statements. These forward-looking statements are
based on the Company’s current expectations and subject to risks
and uncertainties that may cause actual results to differ
materially, including risks related to market competition, the
results of and risks associated with research and development,
risks and uncertainties associated with sales, marketing and
distribution requirements, and other risks detailed from time to
time in the Company’s reports filed with the Securities and
Exchange Commission, including its Form 10-Q for the quarter ended
September 30, 2019. Incyte disclaims any intent or obligation to
update these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20191219005068/en/
Media Catalina Loveman +1 302 498 6171
cloveman@incyte.com
Investors Michael Booth, DPhil +1 302 498 5914
mbooth@incyte.com
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jun 2024 to Jul 2024
Incyte (NASDAQ:INCY)
Historical Stock Chart
From Jul 2023 to Jul 2024